Switch theme
Sign up to access all valuation multiples
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
1949
17.3K+
LTM Revenue $1.1B
LTM EBITDA $207M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ipca Laboratories has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $207M.
In the most recent fiscal year, Ipca Laboratories achieved revenue of $1.0B and an EBITDA of $189M.
Ipca Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ipca Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $737M | XXX | $722M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $207M | XXX | $189M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $159M | XXX | $156M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $98.5M | XXX | $86.4M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $133M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ipca Laboratories's stock price is INR 1424 (or $17).
Ipca Laboratories has current market cap of INR 361B (or $4.2B), and EV of INR 363B (or $4.3B).
See Ipca Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $4.2B | XXX | XXX | XXX | XXX | $0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ipca Laboratories has market cap of $4.2B and EV of $4.3B.
Ipca Laboratories's trades at 4.2x EV/Revenue multiple, and 23.5x EV/EBITDA.
Equity research analysts estimate Ipca Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ipca Laboratories has a P/E ratio of 43.0x.
See valuation multiples for Ipca Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 20.6x | XXX | 23.5x | XXX | XXX | XXX |
| EV/EBIT | 26.8x | XXX | 29.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 43.0x | XXX | 52.3x | XXX | XXX | XXX |
| EV/FCF | 64.8x | XXX | 67.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIpca Laboratories's last 12 month revenue growth is 12%
Ipca Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
Ipca Laboratories's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ipca Laboratories's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ipca Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ipca Laboratories acquired XXX companies to date.
Last acquisition by Ipca Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Ipca Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ipca Laboratories founded? | Ipca Laboratories was founded in 1949. |
| Where is Ipca Laboratories headquartered? | Ipca Laboratories is headquartered in India. |
| How many employees does Ipca Laboratories have? | As of today, Ipca Laboratories has 17.3K+ employees. |
| Who is the CEO of Ipca Laboratories? | Ipca Laboratories's CEO is Mr. Pranay Godha. |
| Is Ipca Laboratories publicy listed? | Yes, Ipca Laboratories is a public company listed on BOM. |
| What is the stock symbol of Ipca Laboratories? | Ipca Laboratories trades under 524494 ticker. |
| When did Ipca Laboratories go public? | Ipca Laboratories went public in 1994. |
| Who are competitors of Ipca Laboratories? | Similar companies to Ipca Laboratories include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ipca Laboratories? | Ipca Laboratories's current market cap is $4.2B |
| What is the current revenue of Ipca Laboratories? | Ipca Laboratories's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Ipca Laboratories? | Ipca Laboratories revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Ipca Laboratories? | Current revenue multiple of Ipca Laboratories is 4.0x. |
| Is Ipca Laboratories profitable? | Yes, Ipca Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ipca Laboratories? | Ipca Laboratories's last 12 months EBITDA is $207M. |
| What is Ipca Laboratories's EBITDA margin? | Ipca Laboratories's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Ipca Laboratories? | Current EBITDA multiple of Ipca Laboratories is 20.6x. |
| What is the current FCF of Ipca Laboratories? | Ipca Laboratories's last 12 months FCF is $65.7M. |
| What is Ipca Laboratories's FCF margin? | Ipca Laboratories's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Ipca Laboratories? | Current FCF multiple of Ipca Laboratories is 64.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
